These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 19424677)
1. The role of redox modulation of class II histone deacetylases in mediating pathological cardiac hypertrophy. Oka S; Ago T; Kitazono T; Zablocki D; Sadoshima J J Mol Med (Berl); 2009 Aug; 87(8):785-91. PubMed ID: 19424677 [TBL] [Abstract][Full Text] [Related]
2. A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Ago T; Liu T; Zhai P; Chen W; Li H; Molkentin JD; Vatner SF; Sadoshima J Cell; 2008 Jun; 133(6):978-93. PubMed ID: 18555775 [TBL] [Abstract][Full Text] [Related]
3. Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy. Kee HJ; Kook H J Biomed Biotechnol; 2011; 2011():928326. PubMed ID: 21151616 [TBL] [Abstract][Full Text] [Related]
4. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Zhang CL; McKinsey TA; Chang S; Antos CL; Hill JA; Olson EN Cell; 2002 Aug; 110(4):479-88. PubMed ID: 12202037 [TBL] [Abstract][Full Text] [Related]
13. Cyclic AMP represses pathological MEF2 activation by myocyte-specific hypo-phosphorylation of HDAC5. He T; Huang J; Chen L; Han G; Stanmore D; Krebs-Haupenthal J; Avkiran M; Hagenmüller M; Backs J J Mol Cell Cardiol; 2020 Aug; 145():88-98. PubMed ID: 32485181 [TBL] [Abstract][Full Text] [Related]
14. Regulation of acetylation of histone deacetylase 2 by p300/CBP-associated factor/histone deacetylase 5 in the development of cardiac hypertrophy. Eom GH; Nam YS; Oh JG; Choe N; Min HK; Yoo EK; Kang G; Nguyen VH; Min JJ; Kim JK; Lee IK; Bassel-Duby R; Olson EN; Park WJ; Kook H Circ Res; 2014 Mar; 114(7):1133-43. PubMed ID: 24526703 [TBL] [Abstract][Full Text] [Related]
15. Mirk/dyrk1B decreases the nuclear accumulation of class II histone deacetylases during skeletal muscle differentiation. Deng X; Ewton DZ; Mercer SE; Friedman E J Biol Chem; 2005 Feb; 280(6):4894-905. PubMed ID: 15546868 [TBL] [Abstract][Full Text] [Related]
16. CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. Backs J; Song K; Bezprozvannaya S; Chang S; Olson EN J Clin Invest; 2006 Jul; 116(7):1853-64. PubMed ID: 16767219 [TBL] [Abstract][Full Text] [Related]
17. STVNa Attenuates Isoproterenol-Induced Cardiac Hypertrophy Response through the HDAC4 and Prdx2/ROS/Trx1 Pathways. Liu F; Su H; Liu B; Mei Y; Ke Q; Sun X; Tan W Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31968660 [TBL] [Abstract][Full Text] [Related]
18. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Vega RB; Harrison BC; Meadows E; Roberts CR; Papst PJ; Olson EN; McKinsey TA Mol Cell Biol; 2004 Oct; 24(19):8374-85. PubMed ID: 15367659 [TBL] [Abstract][Full Text] [Related]
19. Suppression of HDAC nuclear export and cardiomyocyte hypertrophy by novel irreversible inhibitors of CRM1. Monovich L; Koch KA; Burgis R; Osimboni E; Mann T; Wall D; Gao J; Feng Y; Vega RB; Turner BA; Hood DB; Law A; Papst PJ; Koditek D; Chapo JA; Reid BG; Melvin LS; Pagratis NC; McKinsey TA Biochim Biophys Acta; 2009 May; 1789(5):422-31. PubMed ID: 19414071 [TBL] [Abstract][Full Text] [Related]
20. Posttranslational modifications of histone deacetylases: implications for cardiovascular diseases. Eom GH; Kook H Pharmacol Ther; 2014 Aug; 143(2):168-80. PubMed ID: 24594235 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]